AstraZeneca Pharma India to sell operational Bengaluru facility, seeking a buyer with Contract Manufacturing Organization capabilities.
AstraZeneca Pharma India intends to divest its Bengaluru production facility, as indicated in a regulatory filing. The company states that the decision to exit the Bengaluru manufacturing site is part of an ongoing strategic review, with a primary focus on the well-being of its employees.
"AstraZeneca Pharma India Limited reaffirms its dedication to enhancing access to innovative medicines in India, aspiring to be trailblazers in scientific advancements, forefront leaders in specialized disease areas, and catalysts for transforming patient outcomes. As part of AstraZeneca's continuous strategic evaluation of its Global Manufacturing and Supply Network, the company plans to divest its manufacturing site in Bangalore in the near future," stated the filing.
The company will prepare the manufacturing site for sale, ensuring it remains fully operational, and initiate the search for a buyer capable of serving as a Contract Manufacturing Organization (CMO) for the products currently produced or packaged at the Bengaluru site. AstraZeneca acknowledges that these plans are contingent upon obtaining the necessary statutory approvals.
Additionally, it stated, "The company fully recognizes the potential impact of this change, and its foremost commitment is to its employees and meeting the needs of patients by ensuring an uninterrupted supply of medicines."
Founded in 1979, AstraZeneca India is headquartered in Bengaluru. AstraZeneca Pharma India Limited (AZPIL), listed as the operating company, is a subsidiary of AstraZeneca Plc, UK. AstraZeneca India employs over 1,400 people nationwide, according to their website.
AstraZeneca Pharma India focuses on the discovery, development, and commercialization of prescription medicines, primarily in four therapy areas: oncology, cardiovascular, renal, and metabolism and respiratory.
